MedPath

Proton therapy of tumors of the head and neck area: Prospective recording of efficiency and side effects at standard clinical doses

Phase 2
Recruiting
Conditions
C01
C02
C03
C04
C05
C06
C07
C08
C09
C10
Registration Number
DRKS00016164
Lead Sponsor
niversitätsklinikum Dresden, Klinik für Strahlentherapie und Radioonkologie
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
456
Inclusion Criteria

Head and neck tumors: squamous cell carcinomas, adenocarcinomas, rare histologies
- Age > 18 years
- ECOG < 2
- Indication for high-dose primary radiotherapy or radiochemotherapy or for high-dose adjuvant radiotherapy or radiochemotherapy
- Treatment (radiation dose, additional systemic therapies) according to current clinical standard possible and planned
- Ability to consent and the patient's present written consent

Exclusion Criteria

- Lack of possibility of MRI planning (e.g. contraindications to performing an MRI)
- Lack of patient compliance
- Missing or limited possibility of reproducible positioning (e.g. due to severe limitation of patient mobility)
- metals in the region to be irradiated (e.g. internal fixator in the affected section of the cervical spine) if they interfere with dose distribution
- Tumors of the skull base or with irradiation area that reaches the skull base in large volume (--> include in Proto-R skull base)

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Evaluation of late toxicity of a proton therapy with clinical standard doses and fractionation schemes<br><br>Primary target:<br>Grade III/ IV Late toxicity (CTCAE 4.0) 2 years after therapy
Secondary Outcome Measures
NameTimeMethod
Evaluation of local tumor control after proton therapy with clinical standard doses and fractionation schemes, evaluation of acute toxicity.<br><br>Secondary targets:<br>Local tumor control rate after 2 years<br>Overall survival after 2 years<br>Acute toxicity > Grade II<br>Late toxicity Grade II<br>
© Copyright 2025. All Rights Reserved by MedPath